ARTICLE | Distillery Therapeutics
Cancer
January 11, 2017 4:37 PM UTC
Mouse studies suggest inhibiting NR1I3 could help prevent circadian disruption-induced hepatocellular carcinoma (HCC). The mouse model of chronic circadian disruption involved switching light and dark...
BCIQ Company Profiles
BCIQ Target Profiles